Piper Sandler Upgrades Elanco Animal Health (ELAN) to Overweight with $30 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Market Position Improvement: Piper Sandler upgraded Elanco Animal Health from neutral to overweight, indicating significant inroads in corporate accounts that are expected to drive further market share growth for the company.
- Price Target Adjustment: The analyst raised Elanco's price target from $24 to $30, reflecting an approximately 23% upside, showcasing market optimism regarding its future performance.
- Zoetis Downgrade: In contrast, Zoetis was downgraded to neutral with a price target cut from $190 to $135, indicating that the current consumer spending environment poses challenges for its business, with only an 8% upside potential.
- Innovation Cycle Impact: Analysts noted that while Zoetis has the best portfolio in animal health Rx, it is facing an innovation air pocket that could last one to two years, potentially affecting its short-term growth outlook.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.50 USD with a low forecast of 22.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.300
Low
22.00
Averages
25.50
High
30.00
Current: 24.300
Low
22.00
Averages
25.50
High
30.00
About ELAN
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
